AC Immune (ACIU) Stock Forecast & Price Target

AC Immune is attractive fundamentally because its differentiated precision-medicine platform spans active immunotherapy, morphomers, and PET tracers, giving it multiple shots on goal across Alzheimer’s and Parkinson’s disease while also enabling patient selection and target engagement. The week-100 VacSYn readout for ACI-7104.056 was especially encouraging, meeting all three primary endpoints and showing a 100% responder rate, robust CSF penetration, and emerging correlations between antibody titers and UPDRS-III stabilization, which supports the company’s active immunotherapy thesis. Financially, it ended the period with CHF 75.4M in total cash resources and runway into 4Q27, while partnerships and milestones such as the $12 million Takeda payment help extend optionality as later-stage datasets for ACI-24.060, ACI-35.030, and ACI-7104.056 mature.

AC Immune is facing a fundamentally weak outlook because its key vaccine cohort may only show whether serum antibody levels rise in a few months, while the historically low 0.1% to 0.5% translation of serum antibodies to CNS antibodies suggests limited biological reach. With no expected interim readouts, the program could be stopped if the higher dose and second adjuvant fail to generate enough induced antibody levels to even plausibly slow cognitive decline. That leaves the company’s pipeline, including ACI-24.060 and other assets, exposed to high clinical risk and continued uncertainty rather than near-term evidence of meaningful efficacy.